Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR-A2009 plus almonertinib versus almonertinib as first-line treatment for EGFR-mutated advanced non-small cell lung cancer
CTR20253767Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Oct 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ruzaltatug rezetecan, almonertinib in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Oct 2025; status: active.
02
Drugs
ruzaltatug rezetecanalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253767.